Biostage to Present at the Cell & Gene Meeting on the Mesa

HOLLISTON, Mass., Sept. 29, 2016 /PRNewswire/ -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that it will be presenting at the Cell & Gene Meeting on the Mesa being held October 5-7, 2016 in La Jolla, CA. Saverio La Francesca, MD, Executive VP and Chief Medical Officer of Biostage, will present on Thursday, October 6, 2016 at 3:15 p.m. PT.

Dr. La Francesca will provide a medical and scientific review as well as outline the Company's expected upcoming near-term corporate, clinical and regulatory milestones that will enable Biostage's transition to a clinical-stage company in the coming months.

Dr. La Francesca will also provide an overview of the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan™ organ implants. Biostage is currently advancing and testing its Cellspan implants in collaborative pre-clinical studies. The Company is currently conducting pre-clinical, large-animal safety studies, for its Cellspan Esophageal Implant product candidate, in compliance with the U.S. Food and Drug Administration (FDA) Good Laboratory Practice (GLP) regulations, in support of Biostage's goal of filing an Investigational New Drug (IND) application with the FDA which the Company expects to file by year end.

A live video webcast of the Company's presentation will be available at: www.meetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine's website shortly after the event.

About the Cell & Gene Meeting on the Mesa
The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract over 800 attendees, fostering key partnerships through more than 700 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Please visit www.meetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at [email protected] and interested media should contact Lyndsey Scull at [email protected].

About Biostage
Biostage is a biotechnology company developing bioengineered organ implants based on the company's new Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan™ organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

Cellspan implants are currently being advanced and tested in collaborative pre-clinical studies. Pre-clinical, large-animal safety studies, conducted in compliance with the FDA Good Laboratory Practice (GLP) regulations, for the Company's Cellspan Esophageal Implant product candidate have begun, in support of Biostage's goal of filing an Investigational New Drug (IND) application with the U.S. FDA in late 2016. The IND will seek approval to initiate clinical trials for its esophageal implant product candidate in humans.

For more information, please visit www.biostage.com and connect with the Company on Twitter and LinkedIn. 

Forward-Looking Statements:
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing our Cellframe technology,  which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for our products; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Logo - http://photos.prnewswire.com/prnh/20160330/349802LOGO

SOURCE Biostage, Inc.

Related Links

http://www.biostage.com